Copyright
©The Author(s) 2023.
World J Gastroenterol. Apr 21, 2023; 29(15): 2261-2271
Published online Apr 21, 2023. doi: 10.3748/wjg.v29.i15.2261
Published online Apr 21, 2023. doi: 10.3748/wjg.v29.i15.2261
Immunotherapy regimen | IMBRAVE150 (NCT03434379) | HIMALAYA (NCT03298451) |
Drugs | Atezolizumab, Bevacizumab | Durvalumab, Tremelimumab |
Drug class combination | PD-L1 inhibitor, VEGF inhibitor | PD-1 inhibitor, CTLA-4 inhibitor |
Study population | Child-Pugh A, ECOG score 0/1, no prior systemic therapy | Child-Pugh A, ECOG score 0/1, BCLC B or C, no prior systemic therapy |
Key difference | Portal vein thrombosis patients included | Portal vein thrombosis patients excluded |
EGD required? | Yes | No |
Overall survival | 19.2 mo (95%CI: 17.0-23.7) | 16.4 mo (95%CI: 14.2-19.6) |
Median progression free survival | 6.8 mo (95%CI: 5.7-8.3) vs 4.3 (95%CI: 4.0-5.6) | 3.8 mo (95%CI: 3.7-5.3) |
Overall response rate | 27.3% (95%CI: 22.5-32.5) | STRIDE arm: 20.1% |
Long-term survival data | Not available | Available |
- Citation: Bhatt A, Wu J. Immunotherapy for recurrent hepatocellular carcinoma. World J Gastroenterol 2023; 29(15): 2261-2271
- URL: https://www.wjgnet.com/1007-9327/full/v29/i15/2261.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i15.2261